Jazz Pharmaceuticals Announces Merger with Actio Biosciences

Details

announced a material definitive agreement to merge with Actio Biosciences, Inc. The merger involves an upfront transaction value of $820,000,000, with potential additional payments of up to $500,000,000 based on development and sales milestones. The transaction is subject to various conditions, including regulatory approvals and the completion of a spin-out of certain non-ABS-1230 programs to a new company, SpinCo, in which Jazz Pharmaceuticals, Inc. will hold a minority stake.

Items reported

About Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc is a global biopharmaceutical company that focuses on developing life-changing medicines for patients in various therapeutic areas. The company's primary function is to research, manufacture, and market drugs that address unmet medical needs, particularly in the fields of neuroscience, oncology, and sleep medicine. Jazz Pharmaceuticals has gained prominence for its innovative products such as Xyrem, used for treating narcolepsy, and Vyxeos, a treatment for certain types of leukemia. Headquartered in Dublin, Ireland, the company operates extensively across North America and Europe, working to advance scientific research in pharmaceuticals. By prioritizing patient care and survival, Jazz Pharmaceuticals plays a significant role in the pharmaceutical industry with its commitment to developing novel therapies. Moreover, the company's strategic collaborations and acquisitions enable it to expand its product portfolio and impact the healthcare sector positively. Jazz Pharmaceuticals continues to be a key player in transforming patient care for complex conditions.